Bullbearadvisor 
Hims & Hers Health is a U.S.-based telehealth and online pharmacy platform founded in 2017 and publicly listed on the NYSE since 2021 investors.com+15en.wikipedia.org+15tradingview.com+15. Its services span sexual health, dermatology, mental health, and more recently, weight-loss treatments—offering both branded drugs like Wegovy and Zepbound as well as compounded alternatives itiger.com+6en.wikipedia.org+6investors.com+6. In Q1 2025, Hims & Hers delivered standout performance: revenue surged 111% year-over-year to $586 million, adjusted EBITDA reached $91 million, and subscriber count climbed to 2.4 million marketwatch.com+15barrons.com+15investors.com+15. While FDA restrictions affected its ability to sell compounded semaglutide, the company has since pivoted to offering branded obesity drugs via partnerships, sustaining its growth outlook marketwatch.com+3barrons.com+3investors.com+3.
52‑Week Trading Range
- High: $72.98
- Low: $13.47 finance.yahoo.com+10indmoney.com+10finance.yahoo.com+1
Analyst Ratings Summary
- MarketBeat (13 analysts): 2 Buys, 8 Holds, 3 Sells → “Reduce” consensus marketwatch.com+10marketbeat.com+10marketbeat.com+10.
- TipRanks (11 analysts): 1 Buy, 8 Holds, 2 Sells → consensus is Hold tradingview.com+6tipranks.com+6public.com+6.
- Public.com (17 analysts): 29% Strong Buy, 6% Buy, 47% Hold, 12% Sell, 6% Strong Sell → overall Hold public.com.
Summary Table
Rating SourceBuyHoldSellTotal AnalystsConsensusMarketBeat28313ReduceTipRanks18211HoldPublic.com———17Hold (%)
Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!
